BioCentury
ARTICLE | Clinical News

Viread tenofovir disoproxil fumarate: Phase II started

July 30, 2012 7:00 AM UTC

NIH's National Institute of Allergy and Infectious Diseases (NIAID) began the double-blind, placebo-controlled, U.S. Phase II NEXT-PrEP trial in about 400 men who have sex with men and are not infected with HIV to evaluate once-daily oral regimens of maraviroc alone, maraviroc plus emtricitabine, maraviroc plus tenofovir disoproxil fumarate and emtricitabine plus tenofovir for 48 weeks. Subjects will be tested for HIV infection at enrollment, weeks 2, 4 and 8, and every 8 weeks thereafter. Those that seroconvert to HIV-positive status will be instructed to stop the PrEP regimen. Subjects will also receive condoms and counseling on how to reduce their risk of becoming infected with the virus. ...